This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Myriad Genetics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $9.093. Myriad Genetics's 10-Year median PS Ratio is 2.9011. Therefore, the Median PS Value for today is $26.38.
As of today (2024-04-25), Myriad Genetics's share price is $18.12. Myriad Genetics's Median PS Value is $26.38. Therefore, Myriad Genetics's Price to Median PS Value for today is 0.69.
The historical rank and industry rank for Myriad Genetics's Median PS Value or its related term are showing as below:
MYGN'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36 Med: 0.62 Max: 0.91
Current: 0.69
During the past 13 years, the highest Price to Median PS Value of Myriad Genetics was 0.91. The lowest was 0.36. And the median was 0.62.
MYGN's Price-to-Median-PS-Value is ranked better than 59.76% of 82
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.84
vs MYGN: 0.69
Myriad Genetics Median PS Value Historical Data
The historical data trend for Myriad Genetics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Myriad Genetics's Median PS Value
For the Diagnostics & Research subindustry, Myriad Genetics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics's Price-to-Median-PS-Value Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Price-to-Median-PS-Value falls into.
Myriad Genetics Median PS Value Calculation
Myriad Genetics's Median PS Value for today is calculated as
10-Year Median PS Ratio is 2.9011.
Myriad Genetics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.093.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (NAS:MYGN) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Myriad Genetics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
18.12
/
26.38
=
0.69
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics Median PS Value Related Terms
Thank you for viewing the detailed overview of Myriad Genetics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Myriad Genetics (Myriad Genetics) Business Description
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MYGN has been successfully added to your 